Compounds and methods for antiviral treatment

Abstract

Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

What is claimed is: 
     
         1 - 40 . (canceled) 
     
     
         41 . A compound of Formula In: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
       
       wherein:
 Ar is a phenyl, pyridinyl or thienyl, wherein phenyl, pyridinyl or thienyl is optionally substituted with 1 to 5 R 6 ; 
 R 1  is H, methyl or azetidinyl; 
 each R 6  is —N(H)S(O) 2 CH 3 , chloro, bromo, or methyl; 
 R 7  is H or methyl; 
 R 8  is methyl, azetidinyl or pyrrolidinyl, wherein azetidinyl or pyrrolidinyl is optionally substituted with one or two hydroxy, NH 2  or CN. 
 
     
     
         42 . The compound of  claim 41  selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         43 . A compound of  claim 42   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         44 . A compound of  claim 42   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         45 . A pharmaceutical composition comprising a therapeutically effective amount of a compound as described in  claims 41 - 44  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         46 . The pharmaceutical composition of  claim 45  further comprising at least one therapeutic agent selected from ribavirin, palivizumab, motavizumab, RSV-IGIV, MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV01 and ALX-0171 and mixtures thereof. 
     
     
         47 . A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound as described in  claims 41 - 44 , or a pharmaceutically acceptable salt thereof. 
     
     
         48 . The method of  claim 47  wherein the Pneumovirinae virus infection is caused by a respiratory syncytial virus. 
     
     
         49 . The method of  claim 47  further comprising administering a therapeutically effective amount of at least one other therapeutic agent selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV, MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV 01 and ALX-0171 and mixtures thereof.